WATERTOWN, Mass. / Sep 03, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the passing of its beloved and respected longtime Chief Financial and Administrative Officer Paul J. Mellett Jr. “The entire Enanta team mourns the loss of Paul, our colleague and friend,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Since joining the Company more than two... Read More

WATERTOWN, Mass. / Aug 21, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025 : Fireside Chat on Wednesday, September 3, 2025 at 8:35... Read More

WATERTOWN, Mass. / Aug 20, 2025 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a... Read More

On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September On Track to Select a STAT6 Development Candidate in 2H 2025 Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor Candidate, in Development for the Treatment of Chronic Spontaneous Urticaria and Other Mast Cell Driven Diseases Operations Supported by Cash and... Read More

WATERTOWN, Mass. / Aug 05, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series. A live webcast... Read More

WATERTOWN, Mass. / Jul 15, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, July 22 at 1:30 p.m. ET as part of Baird’s Biotech Discovery Series. A live webcast of the event will be... Read More

MAVYRET ® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate 1 *† FDA Approval Now Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis If Left Untreated, Patients with Acute HCV Could Progress to Chronic Disease, Including Cirrhosis or Liver Cancer 2 Glecaprevir, One of the Two... Read More

WATERTOWN, Mass. / May 27, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET... Read More

WATERTOWN, Mass. / May 22, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43 rd Annual Meeting of... Read More

Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8... Read More

WATERTOWN, Mass. / Apr 08, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral presentation as an ePoster... Read More

WATERTOWN, Mass. / Mar 17, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will present at the at the H.C. Wainwright 3 rd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 27, 2025 at 11:00 a.m. ET. A live webcast... Read More

WATERTOWN, Mass. / Mar 12, 2025 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13 th International RSV... Read More

On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as... Read More

WATERTOWN, Mass. / Dec 24, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta’s patent infringement... Read More

Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and... Read More

Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET WATERTOWN, Mass. / Dec 06, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline... Read More

On Track to Report Topline Results for RSVPEDs, a Phase 2 Study of Zelicapavir in Infants and Children Infected with Respiratory Syncytial Virus (RSV), in December Announced Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected with RSV Expands Immunology Portfolio with the Introduction of a New Discovery Program Focused on STAT6 Inhibition and the Nomination of EPS-1421, a... Read More

Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Compared to Placebo Favorable Safety and Tolerability Observed Conference Call and Webcast to Discuss Data at 8:30 a.m. ET Today WATERTOWN, Mass. / Sep 26, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company... Read More

WATERTOWN, Mass. / Sep 03, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of management will participate in three investor conferences being webcast in September: Baird 2024 Global Healthcare Conference: Fireside Chat at 2:35 p.m. ET on September 10, 2024... Read More

Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retained Royalties... Read More

WATERTOWN, Mass. / May 29, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare... Read More

WATERTOWN, Mass. / May 07, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences... Read More

Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March 31, 2024, as well as Continuing Retained Royalties WATERTOWN, Mass. /... Read More

WATERTOWN, Mass. / Apr 30, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal... Read More

WATERTOWN, Mass. / Apr 30, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will... Read More

WATERTOWN, Mass. / Apr 29, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at... Read More

WATERTOWN, Mass. / Apr 17, 2024 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company’s SPRINT ( S ARS-Cov-2 PR otease IN hibitor T reatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being... Read More

WATERTOWN, Mass. / Mar 06, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at Leerink Partners Global... Read More

Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candidate Selection Targeted for 2024 Cash and Marketable Securities Totaled $337.2 Million at December 31, 2023 WATERTOWN, Mass. / Feb 07, 2024 /... Read More

WATERTOWN, Mass. / Feb 06, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Oppenheimer 34 th Annual... Read More

WATERTOWN, Mass. / Jan 31, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2023 after the U.S. market closes on February 7, 2024. Enanta management will host a conference... Read More

Expansion into Immunology with New Discovery Program of Oral KIT Inhibitors Addressing High Unmet Need in Chronic Spontaneous Urticaria (CSU); Development Candidate Selection Targeted for 2024 Expect Topline Data from at Least One Phase 2 Study of Zelicapavir (EDP-938), an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV), in 3Q 2024, Pending Continuation of a Normal Northern Hemisphere RSV Season... Read More

WATERTOWN, Mass. / Jan 03, 2024 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 9:45 a.m. PT in... Read More

WATERTOWN, Mass. / Nov 22, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023 at 7:55 a.m. ET in... Read More

Initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024 Streamlined Business and Significantly Lowered 2024 R&D and G&A Spending Guidance to Support Ongoing Operations Cash and Marketable Securities Totaled $370 Million at September 30, 2023 WATERTOWN, Mass. / Nov 20, 2023 / Business Wire /... Read More

WATERTOWN, Mass. / Nov 13, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023. Enanta management will host a conference call... Read More

Webcast to be Held on Friday, October 20, 2023 at 8:00 a.m. ET WATERTOWN, Mass. / Oct 13, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the... Read More

WATERTOWN, Mass. / Sep 17, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on... Read More

WATERTOWN, Mass. / Sep 07, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at... Read More

WATERTOWN, Mass. / Aug 31, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that members of management will participate in four investor conferences being webcast in September and provide a business update: Wells Fargo Securities Healthcare Conference: Fireside Chat at 2:15 p.m. ET on... Read More

Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 Royalty Revenue for the Quarter was $18.9 Million WATERTOWN, Mass. / Aug 07, 2023 / Business Wire / Enanta... Read More

WATERTOWN, Mass. / Jul 31, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after the U.S. market closes on August 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET to... Read More

Generally Safe and Well-Tolerated up to 800 mg for Seven Days with Pharmacokinetics Supportive of Once-Daily Dosing All Doses Resulted in Strong Exposure Multiples Against Both RSV A and B Strains Human Challenge Study to be Initiated by Early Fourth Quarter 2023 WATERTOWN, Mass. / Jun 20, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel,... Read More

WATERTOWN, Mass. / Jun 07, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held... Read More

WATERTOWN, Mass. / May 31, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global Healthcare Conference on June 7, 2023 at 12:30 p.m. ET in New York, NY. A live webcast of the... Read More

WATERTOWN, Mass. / May 09, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May: JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on May 16,... Read More

Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19 Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET ® /MAVIRET ® Royalties for an Upfront Payment of $200 Million On Track to Report Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory... Read More

Study Met Primary Endpoints of Safety and Tolerability Dose-Dependent Improvement in Total Symptom Score Observed with EDP-235 Treatment Compared to Placebo, Achieving Statistical Significance as Early as One Day After First Dose No Difference in Viral Load Reduction; Rapid Decline Observed in All Study Arms Conference Call and Webcast Today at 4:30 p.m. ET WATERTOWN, Mass. / May 08, 2023 / Business Wire / Enanta... Read More

WATERTOWN, Mass. / May 02, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2023 after the U.S. market closes on May 8, 2023. Enanta management will host a conference call at 4:30 p.m. ET to... Read More

Non-Dilutive and Strengthens Balance Sheet Competitive Process Results in the Sale of 54.5% of the MAVYRET ® /MAVIRET ® Royalty Interest, Subject to a 1.42x Cap Sale Proceeds to Fund Continuing Clinical Development Across Virology Pipeline WATERTOWN, Mass. / Apr 25, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral... Read More

Preclinical Data Demonstrate EDP-235’s Superior Target Tissue Distribution and Cell Penetration Compared to Other Protease Inhibitors New Preclinical Pharmacokinetic Data Highlight EDP-323’s Strong Bioavailability and Favorable Tissue Targeting WATERTOWN, Mass. / Apr 17, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for... Read More

WATERTOWN, Mass. / Apr 06, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDP-323, Enanta’s L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV). "Receiving Fast... Read More

WATERTOWN, Mass. / Apr 05, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory... Read More

WATERTOWN, Mass. / Mar 08, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held... Read More

WATERTOWN, Mass. / Feb 07, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal first quarter ended December 31, 2022. “We begin 2023 in a strong position and poised for success with multiple upcoming milestones across our pipeline. Notably, we are excited to... Read More

WATERTOWN, Mass. / Feb 07, 2023 / Business Wire / Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 8:40 a.m. ET. A live webcast of the... Read More

WATERTOWN, Mass. / Jan 31, 2023 / Business Wire / Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2022 after the U.S. market closes on February 7, 2023. Enanta management will host a conference call at 4:30 p.m. ET... Read More

Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission Expands Robust COVID-19 Antiviral Portfolio With a New Research Program Developing SARS-CoV-2 Papain-Like Protease Inhibitors Introduces New Research Program Targeting Human Metapneumovirus (hMPV)... Read More

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on January 10, 2023 at 3:00 p.m. PT. A live webcast of the presentation will be accessible by visiting the “Events and Presentations”... Read More